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Introduction
Previously, we have studied a case of melanoma displaying the well-agreed clinical and histological characteristics of "spontaneous" tumor regression (1) . It was initially shown by immu- nohistochemical experiments that T cell receptor (TCR)' a/ (1) . PCR-based molecular analysis of the TCR f3 chains expressed by the tumor-infiltrating lymphocytes (TIL) was performed directly in situ demonstrating the overrepresentation of a limited number of V: gene segments, in particular Vf316 (22 vs. 4% in PBL). Extensive sequence analysis ofthe V-D-Jjunctional regions of the V#116 transcripts expressed in situ showed that 84% of them corresponded to a unique mRNA, while the control VJ3 16 sequences from autologous PBL were polyclonal ( 1 ) . These experiments demonstrated that clonal T cell populations were indeed selected and amplified at the tumor site, but were not informative regarding the function ofthe corresponding lymphocytes. It was subsequently attempted to characterize the Vf 16 + T cells through in vitro generation of cell lines and clones derived from the TIL. This attempt failed although we could characterize other T cell clones overgrowing in the culture while being less dominant in vivo (2) . Note that one of them, expressing the Vfl 13 gene segment, was shown to display high levels of cytotoxicity against the autologous tumor cells (2) . Why the cell type most represented (i.e., Vol 6') in vivo displayed a relatively poor capacity of expansion in vitro remains unclear.
In an attempt to circumvent this difficulty and characterize the Vfl16 cells, we have generated here a specific anti-V316 (7) . Each mAb was used at a saturating concentration predetermined by titration curves on positive cloned cell lines.
Human HLA-reactive pregnancy sera (anti-A3, anti-A10, anti-B14, anti-B35) were kindly provided by Dr. C. Raffoux (Hopital Saint Louis, Paris, France). Single-and two-color indirect immunofluorescence analyses were performed using an Elite flow cytometer (Coulter Electronics Inc., Hialeah, FL) as described previously (7).
Generation ofmAb against human Vfi16 gene segment. Production of a V(316 transfectant cell line was performed as described by Romagne et al. (8) . Briefly, cDNA was prepared from PBL and submitted to PCR amplification using a CB-specific antisense primer (8) and a V# 16-specific sense primer designed to introduce an EcoRI restriction site as well as the CCACC Kozak sequence (9) in front of the AUG codon (5'-GCGAATTCCACCATGGTTTCCAGGCTTCTCAGTT-3'). Amplified products were cloned into the pBSmCB215 vector (8).
After subsequent XhoI-NotI double restriction digest the hV# fragment was subcloned into the NT expression vector (F. Romagne, unpublished results) corresponding to pSV2neo with insertion of the SRa promoter (10) . The recombinant construct (V16NT) was then electroporated into DOIS-19 cells ( 11 ) together with the pCA 258 plasmid for high yield coexpression ofthe CD3zeta chain ( 12) . After selection for G418 resistance TCR-positive cells were subsequently identified by flow cytometry as described (8) .
BIOZZI mice were immunized with transfectants expressing a chimeric TCR f3 chain that includes the hVf16 segment ( 13) . Spleen cells from the immunized animals were then fused to the NS-1 nonsecreting myeloma ( 14) . Supernatants of growing hybridoma cells were screened for the ability to produce an anti-V#16 mAb as described by Immunohistochemical staining procedures. Anti-VB16 mAb was used at 1:50 dilution selected after a series of preliminary experiments performed to assess the optimal experimental conditions. As controls we have used several mAbs such as pan-TCR a/lB reagent (BMA 031 mAb), pan-TCR y/5 reagent (anti-TCR6l mAb), and other mAbs against T cell-associated antigens (CD3, CD4, CD8). A polyclonal biotinylated sheep antibody to mouse Ig (reactive with all mouse isotypes) and a streptavidin-biotinylated peroxidase complex (all obtained from Dako, Glostrup, Denmark) served as a detection system for the primary antibody. 3-Amino-9-ethylcarbazole (Dako) was used ( 18 ) . In particular, purified TA-37+ cells from peripheral blood of normal donors were shown to express Vf1l6 transcripts exclusively while displaying a highly polymorphic TCR Va repertoire (data not shown). TA-37 mAb reacts with 2-4% of peripheral CD3 + T lymphocytes in healthy individuals (data not shown).
As expected from previous studies (2), the IL-2-dependent TIL cell lines derived from the regressive lesion after stimulation with autologous tumor cells and/or autologous EBVtransformed B cells (EBV-B) were found to contain -1% TA-37+ cells (Fig. 1 A) . One ofthem was subjected to several cycles of purification with TA-37 (using immunomagnetic beads) and subsequent culture with IL-2. The cell line obtained after 10 d of additional expansion consisted of 88% V 136+ cells (see Fig. 1 B) . The purity was eventually increased up to 98% V3 116+ cells through a second round ofimmunomagnetic separation (Fig. 1 C) .
Flow cytometry analysis of this cell line showed a CD2', CD3+, CD4-, CD8+, CD56-, TCR a/a+, TCR y/6-phenotype (data not shown). TCR Va and V(3 gene segment subfamilies expressed in the cells were analyzed after PCR amplification with a series of previously described TCR-V subfamilyspecific oligonucleotides (16) . These T lymphocytes were found to express a unique V#3 subfamily, namely V3 16, as well as a unique VA4 gene segment (data not shown). Characterization of the V 16 transcripts showed the presence of a unique Vf16-LRDSWN-J32.1 junctional sequence (Table I) , corresponding to that found in 38 of45 cDNA tested from the V: 16 mRNAs expressed in situ (1) . Sequence analysis of the Va4 gene segment also revealed the presence of a unique transcript with a Va4-IPQGG-JGermd junctional sequence (Table I) . Together, these data demonstrated that the cell line was made of a unique V16+/Va4+ T lymphocyte, which does correspond to the clone selected and expanded at the tumor site.
Functional characterization of the Vf316+ TIL-derived T cell line. The V 16+ cells were tested in standard 51Cr release assay against a panel of autologous and allogeneic target cells.
As shown in Fig. 2 , V# 1 6 cells displayed high levels ofcytotoxicity (> 70% specific lysis at an E/T ratio of 5:1) against the autologous melanoma cell line (M10) while failing to lyse other control targets including two allogeneic melanoma cell lines (Ml 1, M 12), autologous and allogeneic EBV-B cell lines, and the NK target K562. Blocking experiments indicated that the Vf 16 cells have the conventional profile of a HLA class I-restricted CTL. Fig. 3 A shows that cytotoxic activity is inhibited by anti-CD3, anti-CD8, anti-TCR a/a, and anti-VB16 mAb at the effector cell level and by W6/ 32 (anti-HLA class I monomorphic mAb) at the target cell level. Furthermore, the presenting HLA class I molecule was characterized with a series of polyclonal antisera corresponding to the HLA phenotype of the patient (HLA-A3, -A10, -B 14, -B35). As shown in Fig. 3 B, the anti-HLA-B 14 serum was found to substantially reduce cytotoxicity as opposed to the other reagents. Note, that the other previously described clone with antitumor activity characterized in this experimental system was also restricted by HLA-B 14, although it expresses a distinct TCR (Vf31 3, Va5, or 15, no homology with the Vtll6 transcript in the junctional sequence [2] ).
Immunohistochemical analysis of the melanoma biopsy with an anti-Vf16 mAb. Because we have previously demonstrated that the great majority ofthe V316 sequences expressed in the tumor correspond to the unique V, I 6-LRDSWN-JB2. 1 CTL (1), here we could use the TA-37 mAb to directly visualize the potential antitumor reaction in the lesion. Immunohistochemical experiments (Fig. 4) revealed a substantial Vf 16 + CTL infiltrate in the peritumoral zone, including the papillary dermis (Fig. 4 B) . Furthermore, VB16+ lymphocytes were found directly in the lesion closely opposed to tumor cells (Fig.  4 C) . Such a distribution represents a common feature of regressive melanoma lesions ( 19) .
Discussion
The concept of immunosurveillance (20) suggests that transformed cells express tumor-associated antigens that trigger an adaptive immune response aimed at rejection of the developing cancer lesions. This theory has proven extremely difficult to substantiate in the human. Perhaps one of the most relevant arguments is the increase of leukemic relapses in series of patients who have received T cell-depleted bone marrow transplants (21 ) . Regarding solid tumors, it is known that a minority of them, such as melanoma, renal cell carcinoma, or bladder cancer, display so-called "spontaneous" regressions and may respond (22, 23) to various types of immunotherapeutic approaches (e.g., BCG, interferons, IL-2, antiidiotypic antibodies). Yet, these observations constitute only indirect evidence, where actual mechanisms leading to tumor regression are largely unknown.
Malignant melanoma is the most studied model in the field ofhuman tumor immunology. It is well known that the tumors are frequently infiltrated by T lymphocytes, and attempts have been made to correlate the degree of these infiltrations with prognosis (24) . In addition, multiple in vitro studies have shown that one can derive from either PBL or TIL IL-2-dependent T cell lines reactive against autologous melanoma cells (reviewed in reference 25). TIL-derived cell lines have even been reinfused to patients in the presence of IL-2 with occasional success (26) . Recently, melanoma-associated antigenic peptides, such as those encoded by the MAGE genes, have been characterized and shown to be recognized by autologous CTL (27, 28). Yet, there is still no direct evidence that effective immune responses may occur physiologically in the course of tumor development. Demonstrating the existence ofsuch antitumor reactions and characterizing their modalities is of critical importance in view of future therapeutic immunomodulation strategies aimed at complementing the conventional cancer treatments. Our approach has been based on studying a potential local immune response when it is proven clinically and histologically that the tumor "spontaneously" regresses. In a first step ( 1), it was found that the selected model lesion is indeed infiltrated by T lymphocytes and that some of these TILs represent in situ amplified clonal cell populations. We show here that the major infiltrating clone is a conventional CTL. It has not been established whether this Ve 16 CTL is indeed "tumor specific." It is, however, clear that the antitumor activity is selective because both autologous PHA blasts (data not shown) and autologous EBV-B cells (the only available nontumoral cell types from the patient) are not lysed. Further studies aimed at identifying the antigenic peptide(s) that determine(s) the recognizition of melanoma cells will clarify this issue. In any case, the present data constitute to our knowledge the first direct evidence that CTL, able to destroy tumor cells, are selected in situ, clonally amplified, and are in a physical situation appropriate to contribute to tumor regression in a clinically relevant (i.e., "spontaneously" regressive) case of a human cancer. These results strongly support the view that the immune system may indeed operate according to the immunosurveillance concept.
